Xencor Inc

Targacept is a biopharmaceutical company engaged in the design, discovery and development of a new class of drugs to treat diseases and disorders of the central nervous system. It is a leader in the field of neuronal nicotinic acetylcholine receptor chemistry and biology. NNRs are found on nerve cells throughout the nervous system and serve as key regulators of nervous system activity. Targacept s product candidates are designed to selectively target specific NNR subtypes and promote therapeutic effects and limit adverse side effects. Targacept has product candidates in clinical development for cognitive impairment, including Alzheimer s disease and age-associated memory impairment, pain and depression. From 1997 to 2000, Targacept was a subsidiary of R. J. Reynolds Tobacco Company. During this time, the company s investigations into the biological effects of nicotine suggested a role for NNRs in the treatment of human disease and led to the creation of Targacept.

ChemDiv Inc. is a fully integrated discovery and development contract research organization (CRO) located in San Diego, Calif., with subsidiaries in Russia and Ukraine. It has expertise in rational drug design, synthetic and medicinal chemistry in various therapeutic areas. With business and logistics operations around the world, the company collaborates with pharmaceutical and biotech partners by enabling them to accelerate research and development programs to higher value clinical inflection points. ChemDiv Inc. has partnerships with Novartis, Bayer CropScience, Genentech Inc., Sanofi-aventis and many more.

Zensun USA Inc is a biopharmaceutical company based in San Diego, CA, specializing in the research and development of innovative medicines for the treatment of serious and life-threatening medical conditions. With a focus on novel drug targets and mechanisms, Zensun has built a diverse product portfolio that includes therapeutics such as Neucardin, ZS-06, and ZS-07, aimed at addressing unmet medical needs. Driven by a commitment to healing and improving the lives of patients, Zensun leverages its expertise in cell signaling and energy metabolism to develop groundbreaking bio-therapeutic products. With a global reach, the company has attracted a team of experts and pioneers in medical research, as well as forward-thinking investors, enabling Zensun to meet the highest global standards in the field of medicine.Generated from the website